Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Benefits of prophylactic percutaneous gastrostomy in patients with nasopharyngeal cancer receiving concurrent chemoradiotherapy: A multicenter analysis.
Dechaphunkul T, Ngamphaiboon N, Danchaivijitr P, Jiratrachu R, Geater SL, Pattaranutaporn P, Jiarpinitnun C, Setakornnukul J, Suktitipat B, Dechaphunkul A. Dechaphunkul T, et al. Among authors: danchaivijitr p. Am J Otolaryngol. 2022 Mar-Apr;43(2):103356. doi: 10.1016/j.amjoto.2021.103356. Epub 2021 Dec 24. Am J Otolaryngol. 2022. PMID: 34972008 Free article.
Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: a multicenter analysis in Thailand.
Ngamphaiboon N, Dechaphunkul A, Setakornnukul J, Dechaphunkul T, Jiratrachu R, Suktitipat B, Jiarpinitnun C, Pattaranutaporn P, Danchaivijitr P. Ngamphaiboon N, et al. Among authors: danchaivijitr p. BMC Cancer. 2020 Jun 3;20(1):518. doi: 10.1186/s12885-020-07024-8. BMC Cancer. 2020. PMID: 32493288 Free PMC article.
Real-world evidence of cisplatin versus carboplatin in patients with locally advanced nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: A multicenter analysis.
Dechaphunkul A, Danchaivijitr P, Jiratrachu R, Dechaphunkul T, Sookthon C, Jiarpinitnun C, Paoin C, Setakornnukul J, Suktitipat B, Pattaranutaporn P, Ngamphaiboon N. Dechaphunkul A, et al. Among authors: danchaivijitr p. Asia Pac J Clin Oncol. 2023 Feb;19(1):51-61. doi: 10.1111/ajco.13668. Epub 2022 Apr 8. Asia Pac J Clin Oncol. 2023. PMID: 35394108
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
Reungwetwattana T, Cho BC, Lee KH, Pang YK, Fong CH, Kang JH, Lee YG, Lim CS, Danchaivijitr P, Lim YN, Lee Y, How SH, Geater S, Lee SS, Min YJ, Kim JH, Lee JS, Lee GW, Soo RA, Lee SY, Choi S, Ahn MJ. Reungwetwattana T, et al. Among authors: danchaivijitr p. J Thorac Oncol. 2023 Oct;18(10):1351-1361. doi: 10.1016/j.jtho.2023.06.016. Epub 2023 Sep 11. J Thorac Oncol. 2023. PMID: 37702629 Free article. Clinical Trial.
Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study.
Thamlikitkul L, Srimuninnimit V, Akewanlop C, Ithimakin S, Techawathanawanna S, Korphaisarn K, Chantharasamee J, Danchaivijitr P, Soparattanapaisarn N. Thamlikitkul L, et al. Among authors: danchaivijitr p. Support Care Cancer. 2017 Feb;25(2):459-464. doi: 10.1007/s00520-016-3423-8. Epub 2016 Oct 6. Support Care Cancer. 2017. PMID: 27714530 Clinical Trial.
Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study.
Korphaisarn K, Danchaivijitr P, Reungwetwattana T, Chewaskulyong B, Thongthieang L, Chindaprasirt J, Maneenil K, Sathitruangsak C, Vinayanuwattikun C. Korphaisarn K, et al. Among authors: danchaivijitr p. Front Oncol. 2021 Apr 29;11:572740. doi: 10.3389/fonc.2021.572740. eCollection 2021. Front Oncol. 2021. PMID: 33996532 Free PMC article.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Mok TSK, et al. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955977 Clinical Trial.
Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
Erman M, Biswas B, Danchaivijitr P, Chen L, Wong YF, Hashem T, Lim CS, Karabulut B, Chung HJ, Chikatapu C, Ingles S, Slimane K, Kanesvaran R. Erman M, et al. Among authors: danchaivijitr p. BMC Cancer. 2021 Sep 14;21(1):1021. doi: 10.1186/s12885-021-08738-z. BMC Cancer. 2021. PMID: 34521387 Free PMC article. Clinical Trial.
Correction to: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
Erman M, Biswas B, Danchaivijitr P, Chen L, Wong YF, Hashem T, Lim CS, Karabulut B, Chung HJ, Chikatapu C, Ingles S, Slimane K, Kanesvaran R. Erman M, et al. Among authors: danchaivijitr p. BMC Cancer. 2021 Nov 9;21(1):1191. doi: 10.1186/s12885-021-08848-8. BMC Cancer. 2021. PMID: 34753434 Free PMC article. No abstract available.
23 results